Silk Road Medical Celebrates Milestone of 100,000 Transcarotid Artery Revascularization (TCAR) Procedures
Silk Road Medical has announced a significant milestone: over 100,000 Transcarotid Artery Revascularization (TCAR) procedures have been performed to date. TCAR, pioneered by Silk Road, is a minimally invasive technique for treating carotid artery disease and reducing stroke risk. The procedure utilizes the ENROUTE® Transcarotid Neuroprotection System with patented flow reversal technology.
Compared to traditional carotid endarterectomy (CEA), TCAR has shown lower risks of acute heart attack and nerve injury, shorter procedure times, and reduced hospital stays. With 15 million people worldwide suffering strokes annually and carotid artery disease contributing to over 800,000 strokes in the U.S. each year, TCAR's efficiency and effectiveness are important for stroke prevention.
Silk Road Medical ha annunciato un traguardo significativo: sono stati eseguiti oltre 100.000 interventi di Rivascolarizzazione Transcarotidea (TCAR) fino ad oggi. Il TCAR, pionieristico di Silk Road, è una tecnica minimamente invasiva per trattare le malattie dell'arteria carotide e ridurre il rischio di ictus. La procedura utilizza il Sistema di Neuroprotezione Transcarotidea ENROUTE® con tecnologia brevettata di inversione del flusso.
Rispetto all'endarterectomia carotidea tradizionale (CEA), il TCAR ha mostrato rischi inferiori di attacco cardiaco acuto e lesioni nervose, tempi di procedura più brevi e degenze ospedaliere ridotte. Con 15 milioni di persone in tutto il mondo che soffrono di ictus ogni anno e la malattia dell'arteria carotide che contribuisce a oltre 800.000 ictus negli Stati Uniti ogni anno, l'efficienza e l'efficacia del TCAR sono importanti per la prevenzione degli ictus.
Silk Road Medical ha anunciado un hito significativo: se han realizado más de 100.000 procedimientos de Revascularización Transcarotídea (TCAR) hasta la fecha. TCAR, pionero de Silk Road, es una técnica mínimamente invasiva para tratar la enfermedad de la arteria carótida y reducir el riesgo de accidente cerebrovascular. El procedimiento utiliza el Sistema de Neuroprotección Transcarotídea ENROUTE® con tecnología patentada de reversión de flujo.
En comparación con la endarterectomía carotídea tradicional (CEA), el TCAR ha mostrado menores riesgos de infarto agudo y daño nervioso, tiempos de procedimiento más cortos y estancias hospitalarias reducidas. Con 15 millones de personas en todo el mundo sufriendo derrames cerebrales anualmente y la enfermedad de la arteria carótida contribuyendo a más de 800.000 derrames en los EE. UU. cada año, la eficiencia y efectividad del TCAR son importantes para la prevención de derrames cerebrales.
실크 로드 메디컬이 중요한 이정표를 발표했습니다: 현재까지 10만 건 이상의 경동맥 재혈관화(TCAR) 시술이 시행되었습니다. 실크 로드가 개척한 TCAR는 경동맥 질환을 치료하고 뇌졸중 위험을 줄이는 최소 침습 기술입니다. 이 시술은 특허받은 유속 역전 기술을 가진 ENROUTE® 경동맥 신경 보호 시스템을 사용합니다.
전통적인 경동맥 내막 절제술(CEA)과 비교할 때, TCAR는 급성 심장마비와 신경 손상의 위험이 낮고, 시술 시간이 짧으며 병원에서의 체류 기간이 단축되었습니다. 매년 전 세계에서 1,500만 명이 뇌졸중으로 고통 받고 있으며, 경동맥 질환이 매년 미국에서 80만 건 이상의 뇌졸중에 기여하고 있으므로 TCAR의 효율성 및 효과는 뇌졸중 예방에 중요합니다.
Silk Road Medical a annoncé un jalon important : plus de 100 000 procédures de Revascularisation Transcarotidienne (TCAR) ont été réalisées à ce jour. Le TCAR, initié par Silk Road, est une technique minimalement invasive pour traiter la maladie de l'artère carotide et réduire le risque d'accident vasculaire cérébral. La procédure utilise le Système de Neuroprotection Transcarotidienne ENROUTE® avec une technologie de retournement de flux brevetée.
Comparé à l'endarterectomie carotidienne traditionnelle (CEA), le TCAR a montré des risques moindres d'infarctus aigu et de lésions nerveuses, des temps de procédure plus courts et des séjours à l'hôpital réduits. Avec 15 millions de personnes dans le monde souffrant d'accidents vasculaires cérébraux chaque année et la maladie de l'artère carotide contribuant à plus de 800 000 AVC aux États-Unis chaque année, l'efficacité et l'efficience du TCAR sont importantes pour la prévention des AVC.
Silk Road Medical hat einen bedeutenden Meilenstein bekannt gegeben: Bis heute wurden über 100.000 transkarotidale Revaskularisationsverfahren (TCAR) durchgeführt. TCAR, das von Silk Road entwickelt wurde, ist eine minimal invasive Technik zur Behandlung von Erkrankungen der Halsschlagader und zur Reduzierung des Schlaganfallrisikos. Bei dem Verfahren wird das ENROUTE® Transcarotid Neuroprotection System mit einer patentierten Flussumkehrtechnologie verwendet.
Im Vergleich zur traditionellen Halsschlagader-endarteriektomie (CEA) hat TCAR geringere Risiken für akute Herzinfarkte und Nervenschäden, kürzere Eingriffszeiten und verkürzte Krankenhausaufenthalte gezeigt. Da jährlich 15 Millionen Menschen weltweit an Schlaganfällen leiden und Erkrankungen der Halsschlagader jährlich zu über 800.000 Schlaganfällen in den USA beitragen, sind die Effizienz und Effektivität von TCAR wichtig für die Schlaganfallprävention.
- None.
- None.
Studied across thousands of patients and supported by hundreds of clinical publications, the TCAR pioneer has continually delivered positive outcomes through minimally invasive techniques
SUNNYVALE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (“Silk Road”) (NASDAQ:SILK), a leading minimally invasive medical device company focused on reducing the risk and impact of stroke, today announced the milestone that more than 100,000 TCAR procedures have been performed to date.
Since its inception, Silk Road has worked diligently to reduce the risk of stroke during treatment of carotid artery disease through innovative technology and minimally invasive techniques. Silk Road is credited with pioneering the TCAR procedure and building the ENROUTE® Transcarotid Neuroprotection System (ENROUTE NPS) that supports the procedure with its patented flow reversal technology. Compared to traditional open surgery (carotid endarterectomy or “CEA”), TCAR has demonstrated a lower risk of acute heart attack, less occurrences of nerve injury, shorter time required to perform the procedure, and a reduced length of stay at the hospital for patients.
“A growing number of patients come to us looking for a solution that is minimally invasive and requires less downtime so they can get back to their daily lives,” said Dr. Gregg Landis, System Chief of Vascular Surgery at Northwell Health. “It’s incredible that Silk Road was able to not only address that need by creating the TCAR procedure, but also achieve such widespread adoption in a short period of time. TCAR has transformed the way we approach treating carotid artery disease while consistently delivering positive patient outcomes.”
Every year, 15 million people worldwide suffer a stroke and carotid artery disease is attributed to more than 800,000 strokes in U.S. patients each year. The growing prevalence of carotid artery disease further reinforces the need for a more efficient, effective and scalable approach to stroke prevention.
“Completing the 100,000th TCAR procedure is the culmination of more than 15 years’ worth of work by members of the Silk Road Medical team and the healthcare providers we work with,” said Chas McKhann, CEO of Silk Road. “As we celebrate this important milestone, we remain excited and motivated to establish TCAR as the standard of care for addressing carotid artery disease.”
To hear more from physicians and patients on how TCAR is enabling Brighter Tomorrows, visit: https://silkroadmed.com/100K
About TCAR with the ENROUTE Transcarotid Neuroprotection and Stent System
TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. The ENROUTE Transcarotid Stent is intended to be used in patients at high risk and standard risk for complications from CEA, in conjunction with the ENROUTE NPS during the TCAR procedure. The ENROUTE NPS is a first in class device used to directly access the common carotid artery and initiate high-rate temporary blood flow reversal to protect the brain from stroke while delivering and implanting the ENROUTE Transcarotid Stent.
About Silk Road Medical
Silk Road Medical, Inc. (NASDAQ: SILK), is a medical device company located in Sunnyvale, California, and Plymouth, Minnesota, that is focused on reducing the risk of stroke and its devastating impact. The company has pioneered a new approach for the treatment of carotid artery disease called Transcarotid Artery Revascularization (TCAR). TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. For more information on how Silk Road Medical is delivering brighter patient outcomes through brighter clinical thinking, visit www.silkroadmed.com and connect on X, LinkedIn and Facebook.
Investor Contact:
Marissa Bych
Gilmartin Group
investors@silkroadmed.com
Media Contact:
Michael Fanucchi
Silk Road Medical
mfanucchi@silkroadmed.com
AP01135.A
FAQ
How many TCAR procedures have been performed using Silk Road Medical's technology?
What are the advantages of TCAR over traditional carotid endarterectomy (CEA)?
How many strokes in the U.S. are attributed to carotid artery disease annually?
What is the key technology used in the TCAR procedure developed by Silk Road Medical (SILK)?
When did Silk Road Medical (SILK) announce reaching the 100,000 TCAR procedures milestone?
